brensocatib
Trade name: Brinsupri
Small moleculeapproved
Approved
Aug 12, 2025
Clinical trial activity
17 trials · 4 clinical orgs · 1 marketing orgs
Phase 1
11
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02303574)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
2020s
- Jan 1, 2020
Earliest Phase 3 Sponsor(trial)
- Jan 1, 2021
Insmed, Inc. — Earliest Phase 2 Sponsor(trial)
- Aug 12, 2025
Earliest FDA Approval
- Aug 12, 2025
Insmed, Inc. — Marketing Organization
Indications
Approved for
Mechanism of action
- Dipeptidyl peptidase IINHIBITOR
CTSC inhibitor
Approval history
- approvedPriority reviewAug 12, 2025
Chemistry & pharmacology
Loading structure…
SMILES
Cn1c(=O)oc2ccc(-c3ccc(C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)cc3)cc21- Mol. weight
- 420.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3900409 ↗
Also known as
- azd7986
- azd7986
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06685835 | Phase 2 | Nov 22, 2024 | Insmed, Inc. |
| NCT06344728 | Phase 1 | Apr 30, 2024 | Insmed, Inc. |
| NCT06178783 | Phase 1 | Dec 27, 2023 | Insmed, Inc. |
| NCT06013241 | Phase 2 | Oct 30, 2023 | Insmed, Inc. |
| NCT05965570 | Phase 1 | Jul 28, 2023 | Insmed, Inc. |
| NCT05826574 | Phase 1 | May 10, 2023 | Insmed, Inc. |
| NCT05517525 | Phase 1 | Oct 4, 2022 | Insmed, Inc. |
| NCT05355935 | Phase 1 | Apr 27, 2022 | Insmed, Inc. |
| NCT05090904 | Phase 2 | Nov 22, 2021 | Insmed, Inc. |
| NCT05652257 | Phase 1 | Aug 13, 2021 | Insmed, Inc. |
| NCT05673603 | Phase 1 | Jul 20, 2021 | Insmed, Inc. |
| NCT04594369 | Phase 3 | Dec 1, 2020 | Insmed, Inc. |
| NCT04817332 | Phase 3 | Jun 5, 2020 | Insmed, Inc., University of Dundee |
| NCT05927597 | Phase 1 | Jan 9, 2019 | Insmed, Inc. |
| NCT02653872 | Phase 1 | Jan 1, 2016 | AstraZeneca, Parexel |
| NCT02303574 | Phase 1 | Dec 1, 2014 | AstraZeneca, Parexel |
| NCT05344508 | N/A | — | Insmed, Inc. |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Insmed, Inc. | For profit | 15 | 14 | 4 | 2019 |
| AstraZeneca | For profit | 2 | 2 | 1 | 2014 |
| Parexel | For profit | 2 | 0 | 1 | 2014 |
| University of Dundee | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Insmed, Inc. | For profit | MKTG | Aug 12, 2025 |